Gene Therapies For Better Kidney Treatments With Purespring Therapeutics
According to the Centers for Disease Control and Prevention, 15 percent of U.S. adults – 37 million people – are living with chronic kidney disease, while global prevalence is estimated to exceed 840 million patients. Despite a clear need for therapies, kidney conditions have proven difficult to treat, often burdening patients with invasive options such as dialysis and transplant.
Richard Francis, CEO of Purespring Therapeutics, a gene therapy company focused on pioneering more accessible, less burdensome treatment options, has spent decades in the biopharmaceutical space trying to commercialize sea-change treatments for patients who need them. In a recent episode of The Business of Biotech, Francis explored the importance of pursuing new treatments for kidney conditions, as well as why he believes Purespring is poised for long-range commercial success.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.